1 2

TIRZ

TIRZ

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$89.99
$89.99
Sale Sold out
Shipping calculated at checkout.
Volume

Tirzepatide — Dual Incretin (GLP-1 + GIP) Receptor Agonist

Tirzepatide is a long-acting peptide that activates both the GLP-1 and GIP receptors. In research, it’s used to study how dual-incretin signaling influences glucose control, appetite pathways, and body-composition trends beyond what single-pathway GLP-1 analogues show.

Identifiers
  • CAS: 2023788-19-2
  • Peptide class: Long-acting incretin analogue (dual GLP-1/GIP)
  • Approx. MW: ~4.8 kDa (sequence/salt form dependent)
  • Design: Modified incretin sequence with a fatty-diacid side chain for albumin binding (extended half-life)
How It Works (Plain English)
  • GLP-1 receptor: supports insulin release, slows gastric emptying, and promotes a natural sense of fullness.
  • GIP receptor: complements GLP-1 by modulating insulin secretion and adipose signaling in a context-dependent way.
  • Together: Dual activation lets researchers observe broader metabolic effects than with GLP-1 alone, including changes in energy intake and fat distribution.
Why Researchers Use It
  • To compare dual-pathway vs single-pathway incretin signaling.
  • To examine glucose tolerance, appetite regulation, and lipid markers.
  • To explore body-composition shifts (including visceral fat) over longer time frames.

Key Studies — What Was Tested, What Changed, Why It Matters

Glucose control and insulin dynamics
  • What was tested: Time-course effects on fasting and post-meal glucose, insulin secretion, and insulin sensitivity.
  • What changed: Smoother glucose curves and stronger post-meal insulin responses vs baseline models; fewer high spikes after feeding.
  • Why it matters: Shows how dual-incretin signaling can reduce metabolic “turbulence,” a useful setup for pancreatic-cell and whole-body glucose-handling studies.
Appetite, gastric emptying, and energy intake
  • What was tested: Central/peripheral signaling related to satiety, meal size, and gastric emptying rate.
  • What changed: Reduced caloric intake, slower gastric emptying, and activation of appetite-regulating centers (brainstem/hypothalamus) in line with incretin biology.
  • Why it matters: Offers a clear model for the brain–gut axis and how it shapes eating behavior and energy balance.
Body-composition and lipid profiles
  • What was tested: Changes in fat/lean mass and circulating lipids during sustained dual-incretin exposure.
  • What changed: Trends toward visceral fat reduction, improved triglycerides, and healthier lipid fractions over time.
  • Why it matters: Helps parse how incretin signaling affects where fat is stored—not just how much—an important distinction in metabolic risk models.

Potential Research Applications

Metabolic Function

  • Glucose tolerance, insulin-secretion assays
  • β-cell function and incretin cross-talk

Appetite & Satiety

  • Neuroendocrine signaling and meal-size control
  • Gastric-emptying kinetics and gut–brain pathways

Body-Composition Research

  • Visceral vs subcutaneous adiposity (CT/MRI/DEXA)
  • Lipid panels and metabolic flexibility

Synergistic Peptides (for Study Design)

Semaglutide (GLP-1)

  • Why pair/compare: Establishes the added value of dual vs single incretin signaling.
  • Angle: Side-by-side insulin, appetite, and imaging endpoints.

AOD-9604

  • Why pair: Used in fat-metabolism research; complements incretin pathways from a different mechanism.
  • Angle: Adipose and mitochondrial markers under combined stimuli.

CJC-1295 (with DAC)

  • Why pair: Probes cross-talk between GH/IGF-1 and incretin axes.
  • Angle: Long-duration metabolic studies tracking glucose + lipid panels.

Design Notes

  • Define arms clearly: GLP-1 only, dual incretin, and combo with endocrine tools.
  • Control for feeding schedule, stress, and activity—these shift outcomes.
  • Document formulation (pH, light exposure) and storage rigorously.

Known Concerns (Context)

  • GI tolerance: Nausea and slower gastric emptying are common observations in incretin research; titration and timing matter.
  • Model sensitivity: Appetite and glucose results can swing with environment; standardize meals, time of day, and stressors.
  • General: Research use only; not for human consumption or therapeutic use.

Follow institutional SOPs for incretin-pathway peptides and metabolic sampling schedules.

Specifications & Handling

  • Form: Lyophilized powder (lot-coded)
  • Purity: ≥ 99% (HPLC/MS verified)
  • Storage: ≤ −20 °C; protect from light/moisture
  • In solution: Aliquot promptly; avoid repeat freeze–thaw
  • Additives: None unless specified per lot
  • Packaging: Tamper-evident; research-only labeling

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

Tirzepatide Peptide Research | Dual Incretin (GLP-1 + GIP) Agonist | Metabolic & Appetite Studies

Keywords: Tirzepatide peptide, dual incretin, GLP-1 GIP agonist, appetite regulation, glucose control, visceral fat research, metabolic science, Base Peptides.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.
Keep Shopping